These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 11197270)

  • 1. Absence of toxicity of ornidazole after a 10-yr continous daily use for Crohn's disease.
    Triantafillidis JK; Nicolakis D; Antoniou A; Hereti I
    Am J Gastroenterol; 2001 Jan; 96(1):254-5. PubMed ID: 11197270
    [No Abstract]   [Full Text] [Related]  

  • 2. Ornidazole in the treatment of active Crohn's disease: short-term results.
    Triantafillidis JK; Nicolakis D; Emmanoullidis A; Antoniou A; Papatheodorou K; Cheracakis P
    Ital J Gastroenterol; 1996 Jan; 28(1):10-4. PubMed ID: 8743067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of Cronh's disease in the acute stage, using ornidazole (Tiberal). Preliminary results].
    Ammann RW; Müller-Schoop J; Knoblauch M
    Schweiz Med Wochenschr; 1978 Jul; 108(28):1075-7. PubMed ID: 97778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ornidazole in the treatment of active Crohn's disease.
    Triantafillidis JK; Manoussakis CA; Papavasiliou E
    Am J Gastroenterol; 1988 Aug; 83(8):892-3. PubMed ID: 3394693
    [No Abstract]   [Full Text] [Related]  

  • 5. Ornidazole in the prevention of recurrence of Crohn's disease.
    Triantafillidis JK; Antoniou A; Emmanoulidis A; Nicolakis D; Barbatzas C; Cheracakis P
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):446-7. PubMed ID: 9789152
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute pancreatitis following doxycycline and ornidazole coadministration.
    Ocal S; Selçuk H; Korkmaz M; Unal H; Yilmaz U
    JOP; 2010 Nov; 11(6):614-6. PubMed ID: 21068497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
    Korzenik JR; Dieckgraefe BK
    Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaposi's sarcoma and cytomegaloviral ileocolitis complicating long-standing Crohn's disease in an HIV-negative patient.
    Cohen RL; Tepper RE; Urmacher C; Katz S
    Am J Gastroenterol; 2001 Oct; 96(10):3028-31. PubMed ID: 11693345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.
    Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D
    Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year.
    Vilien M; Dahlerup JF; Munck LK; Nørregaard P; Grønbaek K; Fallingborg J
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1147-52. PubMed ID: 15153167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract]   [Full Text] [Related]  

  • 16. Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab.
    Pajares JA; Hernández L; Menchén P; Menchén L
    Am J Gastroenterol; 2009 Jul; 104(7):1863-4. PubMed ID: 19436276
    [No Abstract]   [Full Text] [Related]  

  • 17. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?].
    Lanyi B; Dienes HP; Kruis W
    Dtsch Med Wochenschr; 2005 Aug; 130(34-35):1944-7. PubMed ID: 16123897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.